Matt Summerville

I was hoping you could drill deeper into the medical portfolio and their performance therein across both EIG and EMG and how we should be thinking about kind of the medium to long-term algorithm

I was wondering if you could talk about how you're thinking about strategic price capture kind of going forward

you expressed, I think, a couple of times in your prepared remarks, a little more optimism with respect to process

can you give a little bit more granularity on the type of organic sales performance and order growth you saw

Can you go through the same kind of analysis specifically the Automation side of the business, where -- how that business is performing

what do you think the right go-forward organic algorithm looks like for that portion of AMETEK

could you maybe provide a little bit more detail on what you are seeing specifically in Paragon and the broader group of medical-related businesses

can you speak more broadly across AMETEK as to the order cadence you've experienced through the first 4 months of the year?

could you talk a little bit about the nature of delays you saw within EIG? And if you started to see some of that break

can you talk about where you were with price cost in '24, what your views on that are for '25 and what you see as AMETEK's ultimate level of price capture this year?

can you provide a deeper assessment or maybe initial assessment on the actionability and quality of A. O. Smith's current M&A pipeline?

are you willing to consider something more transformational, maybe add another leg to the stool

Does what you're seeing in China and really what you've experienced in China over the last several years, does that change the growth algorithm

Maybe it's not clear to me what channels you're maybe deemphasizing a bit versus where you're placing greater emphasis

Can you give a bit more context as to why you expect to see what sounded like maybe some sustained inflection from here in the life sciences portion of HST?

Can you also maybe highlight just how you saw incoming orders cadence through the first 3 months of the year, what you're seeing in April thus far across the businesses?

is there a way to sort of parse out how much of that may have been kind of year-end budget flush

talk about the order cadence that you saw in FMT, kind of the chem, O and G and ag side of the business

you referenced your data center-related exposure. Can you maybe size that up for us

Have you seen any discernible trend in sequential cadence in orders

Can you just kind of review how you're thinking about Nordson's positioning therein, views on cycle durability and maybe a little bit more granularity

should we assume that growth going forward is now sustainably on track to consistently deliver the algorithm as you guys have historically advertised

maybe if you can just comment on what you're seeing from an M&A standpoint

can you just give a little bit more granularity as to the weather impact you saw in the quarter

maybe just talk in a little bit more detail about M&A actionability from here on out at 2.1x net leverage

Is there a way to quantify how much of that business today is being driven by various categories of high-performance computing

If you look at your tariff exposure on an annualized basis, what does it look like? If it's completely unmitigated

Help me understand a little bit more about what played out in your electronics-related business in the quarter?

When do we start to see year-on-year growth more aligned to the long-term trajectory you lay out for that business?

Can you maybe talk about the monthly order cadence you experienced in fiscal first quarter? What you're seeing thus far in fiscal Q1

can you maybe just flush out then what your kind of baseline expectation is for organic at the segment level for IPS and MFS?